A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor.

Trial Profile

A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs Lesinurad (Primary)
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms LIGHT
  • Sponsors Ardea Biosciences; AstraZeneca
  • Most Recent Events

    • 23 Sep 2017 Results related to this study and it's extension study (refer CTP: 229400) were published in the Rheumatology
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 13 Dec 2013 Top-line results reported in an AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top